FOLFOX4方案一线治疗晚期大肠癌近期疗效分析

Analysis of Short-Term Effects of FOLFOX4 as First-Line Treatment on Advanced Colorectal Carcinoma

目的观察FOLFOX4方案一线治疗晚期大肠癌的近期疗效和毒副反应。方法32例晚期大肠癌给予OXA 85 mg/m^2静脉滴注2 h，d1，CF 400 mg/m^2静脉滴注2 h，5-Fu 400 mg/m^2静脉推注后以600 mg/m^2持续滴注22 h，d1，2。每2周重复为1个周期，4-6个周期后判定疗效。结果32例平均治疗周期数为9个，总有效率为50.0%，疾病控制率为90.6%，中位至疾病进展时间8.5个月。骨髓抑制为主要毒副反应，粒细胞减少发生率达75.0%，其次是胃肠道反应和周围神经毒性。结论FOLFOX4方案一线治疗晚期大肠癌疗效较好，毒副反应可以耐受。

Objective The short-term efficacy and toxicity of FOLFOX4 were evaluated for treating patients with advanced colorectal carcinoma as the first-line chemotherapy. Methods Oxaliplatin 85 mg/m^2 infusion for 2 hours, d1, CF 400 mg/m^2 infusion for 2 hours followed by 5-Fu 400 mg/m^2 iv bolus and 600 mg/m^2 infusion for 22 hours, d1,2. Every two weeks were a cycle. The patients were evaluated after 4-6 cycles. Results 32 patients who were experienced 9 cycles averagely entered this study： the total response rate was 50.0%, and the disease control rate was 90.6%. Median survival time was 8.5 months. The main adverse effects were myelosuppression, neutropenia was 75.0% , nausea/vomiting 53.1% , neurosensory toxicity 40.6%. Conclusion FOLFOX4 was effective for the first-line chemotherapy of advanced colorectal carcinoma, and the toxicity was mild and tolerable.